KRAS and non-small cell lung carcinoma: Recently, Chen et al. reported that atorvastatin overcame gefitinib resistance with the synergistic inhibition of MEK and PI3K/Akt pathways in KRAS mutant NSCLC cells [42], whose proof-of-concept was proven in a randomized study demonstrating the efficacy of gefitinib plus simvastatin in NSCLC patients [43].